Incubator announces new program, Houston startup names new partner, and more energy innovation news

short stories

Here's your roundup of energy innovation news coming out of Houston. Photo via Getty Images

Houston's energy innovation ecosystem has seen a busy spring season, with startup accelerator cohorts announced, expanded corporate partnerships, and recent funding raised.

In this roundup of short stories within Houston energy innovation, a startup enters into a strategic partnership, Greentown Labs announces a new accelerator, and more.

Syzygy taps global company to lead scaling for tech development 

Syzygy has brought on a new partner that's key to its future growth and tech production. Photo via Emerson

Houston-based Syzygy Plasmonics, which has developed a light-based catalyst reactor technology that originated out of Rice University, has selected global technology and software company Emerson (NYSE: EMR) to automate electrification of chemical production processes.

The reactor technology uses light instead of thermal energy for chemical manufacturing. The all-electric production method has the opportunity to replace fossil fuel-based combustion, making energy generation more sustainable. Syzygy estimates, according to the news release, that its reactor systems could eliminate 1 gigaton of CO2 emissions by 2040.

“We are excited to advance this opportunity with Emerson not only for its automation technologies and software but also its sustainability leadership and domain expertise in chemical engineering, electrification and hydrogen production,” says Syzygy CEO Trevor Best in the release. “As we expand beyond traditional paradigms of reactor technology and launch a new way to electrify chemical manufacturing, we wanted a technology partner who can help us scale our technology efficiently, safely and reliably.”

Emerson will provide its suite of hardware, software, and services for the Syzygy modular reactors.

"Emerson is excited to collaborate with Syzygy Plasmonics on such promising technology that could have a significant impact on industries that are some of the most challenging to decarbonize," says Peter Zornio, CTO at Emerson. “This aligns with Emerson’s culture of innovation that takes on our customers’ biggest challenges.”

Greentown Labs announces applications opening for Shell accelerator

Shell is seeking energy tech companies. Photo via greentownlabs.com

Greentown Labs, a climatetech incubator co-located in Houston and Boston, has teamed up with Shell for a Greentown Go program, geared at accelerating startup-corporate partnerships, to focus on technologies for carbon utilization, storage, and traceability.

Greentown Go Make 2023 zeroing in on alternative carbon feedstocks for carbon-intensive commodities; biogenic and nature-based solutions; and solutions for carbon storage and traceability, according to a news release.

Applications are open now, and the selected startups will have access to mentorship from Shell and Greentown's networks, desk space and membership within Greentown, $15,000 in non-dilutive grant funding, and educational workshops throughout the duration of the six-month program.

“Greentown Go brings together groundbreaking climatetech startups and the corporations that can help commercialize and scale their technologies,” says Kevin T. Taylor, interim CEO and CFO at Greentown Labs, in a news release. “Every Greentown Go program aims to drive climate impact and accelerate the energy transition. We look forward to working with Shell, a long-time Greentown partner, on this important program and supporting the latest innovations in carbon utilization, storage, and traceability.”

The program will help support Shell’s strategy through the development and scaling of technologies for carbon utilization, storage, and traceability across chemicals, carbon fuels, and more.

“Collaboration to accelerate technology development is critical to developing the energy solutions we need for a low-carbon energy future, and I am excited to see what novel technologies arise from startups participating in the Greentown Go Make 2023 program,” says Ed Holgate, commercial partnerships manager at Shell.

Chevron Technology Ventures adds Canadian startup to its Catalyst Program

Motive.io ia using AI to optimize workforce training. Photo via Motive.io

Chevron Technology Ventures announced the addition of Vancouver-based Motive.io, which provides immersive training solutions that leverage virtual and augmented reality technologies, to its Catalyst program. The program seeks out and helps to grow breakthrough technologies and solutions that have the potential to disrupt the energy industry.

"We are honored and thrilled to be selected as part of Chevron Technology Ventures' Catalyst program," says Ryan Chapman, CEO of Motive.io, in a news release. "Selection for this program represents a tremendous opportunity for Motive.io to collaborate with Chevron Technology Ventures as we continue to advance our cutting-edge immersive training solutions for the energy sector."

Motive.io's technology, called the XR Management System, "aims to revolutionize how companies train their employees by providing realistic and interactive simulations that allow learners to practice their skills in a safe and controlled environment," according to a news release.

From Your Site Articles
Chevron has brought on two startups as a part of its Catalyst Program that helps accelerate and mature energy tech companies. Photo via Getty Images

Chevron's Houston-based venture group taps two companies for its startup-focused program

energy tech

Chevron's corporate venture arm that invests into energy tech innovation and supports startups within the industry has tapped two companies for its Chevron Technology Ventures Catalyst Program.

Entech Solutions and mIQroTech have both recently been named new partners in the program, which allows the startups support and guidance during growth and acceleration from Chevron and its network.

Norway-based Entech Solutions AS has developed itsSuperstage Pinpoint Stimulation to address high intensity stimulation in increasingly long horizontal wells, according to a press release. The product aims to improve production performance and lower costs.

"Collaboration with Chevron will allow us to demonstrate Superstage efficiencies in a variety of basins worldwide," says Anthony Kent, co-inventor of Superstage and Entech's General Manager for North America, in the release.

"Working with a leading global operator gives us access to expertise needed to standardize this robust and versatile hardware technology," he continues.

Meanwhile, Tampa, Florida-based mIQroTech is addressing pipeline leak concerns within the energy industry by using artificial intelligence and internet of things. The startup joined the Catalyst Program in July.

"Our goal is to deliver a transformative change to the global oil and gas industry," says founder and chief executive officer, Meade Lewis, in a press release.

"Better data, analytics, and intelligence will add efficiencies to pipeline operations and empower more informed and faster decision-making. We appreciate that Chevron recognizes our potential to deliver solutions to enable safer delivery of oil and gas," Lewis continues.

The company, which has received investments from Plug and Play, Ocean Capital, Republic, and Harvard Business School Alumni Angels, and more, will focus on growing its team and customer base.

Chevron also recently contributed to Houston-based ThoughtTrace's $10 million series B round in May and signed on as a partner for the Houston expansion of cleantech accelerator Greentown Labs.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings